William Blair Has Bullish Forecast for Insulet Q4 Earnings

Insulet Co. (NASDAQ:PODD) – Research analysts at William Blair increased their Q4 2024 earnings per share estimates for shares of Insulet in a research report issued on Monday, November 11th. William Blair analyst M. Andrew now anticipates that the medical instruments supplier will post earnings per share of $1.18 for the quarter, up from their prior estimate of $0.99. The consensus estimate for Insulet’s current full-year earnings is $3.17 per share. William Blair also issued estimates for Insulet’s Q1 2025 earnings at $0.83 EPS, Q2 2025 earnings at $0.84 EPS and FY2025 earnings at $3.91 EPS.

PODD has been the subject of a number of other research reports. Citigroup increased their price objective on shares of Insulet from $250.00 to $275.00 and gave the company a “buy” rating in a report on Tuesday, October 1st. UBS Group lifted their price objective on Insulet from $211.00 to $223.00 and gave the stock a “neutral” rating in a research report on Friday, August 9th. Morgan Stanley upped their target price on Insulet from $234.00 to $317.00 and gave the company an “overweight” rating in a report on Monday. Raymond James lifted their price target on Insulet from $213.00 to $260.00 and gave the stock an “outperform” rating in a report on Monday, October 14th. Finally, Canaccord Genuity Group upped their price objective on shares of Insulet from $236.00 to $269.00 and gave the company a “buy” rating in a report on Wednesday, September 25th. Three research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $253.27.

Insulet Price Performance

Shares of NASDAQ PODD opened at $261.16 on Wednesday. The firm has a 50-day simple moving average of $236.86 and a 200-day simple moving average of $206.85. The company has a quick ratio of 2.80, a current ratio of 3.68 and a debt-to-equity ratio of 1.21. The stock has a market capitalization of $18.32 billion, a price-to-earnings ratio of 44.72, a price-to-earnings-growth ratio of 4.26 and a beta of 1.22. Insulet has a 52 week low of $160.19 and a 52 week high of $279.40.

Hedge Funds Weigh In On Insulet

Institutional investors have recently modified their holdings of the business. Blue Trust Inc. grew its position in shares of Insulet by 84.1% during the third quarter. Blue Trust Inc. now owns 127 shares of the medical instruments supplier’s stock worth $30,000 after buying an additional 58 shares in the last quarter. International Assets Investment Management LLC purchased a new position in Insulet in the second quarter worth approximately $32,000. Venturi Wealth Management LLC grew its holdings in Insulet by 633.3% during the 3rd quarter. Venturi Wealth Management LLC now owns 154 shares of the medical instruments supplier’s stock worth $36,000 after acquiring an additional 133 shares in the last quarter. UMB Bank n.a. increased its position in shares of Insulet by 81.0% in the 2nd quarter. UMB Bank n.a. now owns 181 shares of the medical instruments supplier’s stock valued at $37,000 after purchasing an additional 81 shares during the last quarter. Finally, CVA Family Office LLC raised its holdings in shares of Insulet by 138.1% in the 2nd quarter. CVA Family Office LLC now owns 250 shares of the medical instruments supplier’s stock valued at $50,000 after purchasing an additional 145 shares in the last quarter.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.